Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 3 of 3 entries
View as:
Phase: N/A
Priority: Normal
Start: 08/01/19
End: 01/03/24
Due: 01/03/25
Phase: N/A
Priority: Normal
Start: 01/04/22
End: 10/18/22
Due: 10/18/23
Phase: N/A
Priority: Normal
Start: 01/17/23
End: 02/28/29
Due: 02/28/30
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| To Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of ABN401 in Patients With Advanced Solid Tumors and Non-Small Cell Lung Cancer Harboring c-MET Dysregulation | NCT04052971 | Abion Inc | user2@example.com | None | 2019-08-01 | 2024-01-03 | 2025-01-03 | - | - | 2025-07-14 |
| To Evaluate the Safety, Pharmacokinetic and the Effect of Food After Administration of ABN401 in Healthy Adult Volunteers | NCT05248074 | Abion Inc | user2@example.com | None | 2022-01-04 | 2022-10-18 | 2023-10-18 | - | - | 2025-07-14 |
| To Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetic Profile of ABN401 in Patients With Advanced Solid Tumors Harboring c-MET Dysregulation | NCT05541822 | Abion Inc | user2@example.com | None | 2023-01-17 | 2029-02-28 | 2030-02-28 | - | - | 2025-07-14 |